Maspin expression, angiogenesis, prognostic parameters, and outcome in malignant melanoma

Journal of the American Academy of Dermatology

Volumn 60, Issue 5, 2009, Pages 758-766

  Chua, Ramon ^a   Setzer, Shannon ^a   Govindarajan, Baskaran ^a   Sexton, Debbie ^a   Cohen, Cynthia ^a   Arbiser, Jack L ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

melanoma; prognosis; tumor suppressor

Indexed keywords

CYCLOOXYGENASE 2; HERMES ANTIGEN; MASPIN; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN; VITRONECTIN RECEPTOR;

ANGIOGENESIS; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MELANOCYTE; MELANOMA; NEVUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ANTIGENS, CD44; CYCLOOXYGENASE 2; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; INTEGRIN ALPHAVBETA3; MALE; MELANOMA; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; SERPINS; TRANSFORMING GROWTH FACTOR BETA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 64749097427     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2009.01.018     Document Type: Article

References (49)

1. Zou Z., Anisowicz A., Hendrix M.J., Thor A., Neveu M., Sheng S., et al. Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. Science 263 (1994) 526-529
2. Xia W., Lau Y.K., Hu M.C., Li L., Johnston D.A., Sheng S., et al. High tumoral maspin expression is associated with improved survival of patients with oral squamous cell carcinoma. Oncogene 19 (2000) 2398-2403
3. Sood A.K., Fletcher M.S., Gruman L.M., Coffin J.E., Jabbari S., Khalkhali-Ellis Z., et al. The paradoxical expression of maspin in ovarian carcinoma. Clin Cancer Res 8 (2002) 2924-2932
4. Zettersten E., Shaikh L., Ramirez R., and Kashani-Sabet M. Prognostic factors in primary cutaneous melanoma. Surg Clin North Am 83 (2003) 61-75
5. Streit M., and Detmar M. Angiogenesis, lymphangiogenesis, and melanoma metastasis. Oncogene 22 (2003) 3172-3179
6. Ribatti D., Ennas M.G., Vacca A., Ferreli F., Nico B., Orru S., et al. Tumor vascularity and tryptase-positive mast cells correlate with a poor prognosis in melanoma. Eur J Clin Invest 33 (2003) 420-425
7. Zamolo G., Gruber F., Cabrijan L., Micovic V., Iternicka Z., and Jonjic N. Influence of tumor thickness and vascularity on survival in cutaneous melanoma. Acta Med Okayama 55 (2001) 289-293
8. Beecken W.D., Kramer W., and Jonas D. New molecular mediators in tumor angiogenesis. J Cell Mol Med 4 (2000) 262-269
9. Vlaykova T., Laurila P., Muhonen T., Hahka-Kemppinen M., Jekunen A., Alitalo K., et al. Prognostic value of tumor vascularity in metastatic melanoma and association of blood vessel density with vascular endothelial growth factor expression. Melanoma Res 9 (1999) 59-68
10. Straume O., Salvesen H.B., and Akslen L.A. Angiogenesis is prognostically important in vertical growth phase melanomas. Int J Oncol 15 (1999) 595-599
11. Vlaykova T., Muhonen T., Hahka-Kemppinen M., Pyrhonen S., and Jekunen A. Vascularity and prognosis of metastatic melanoma. Int J Cancer 74 (1997) 326-329
12. Craft P.S., and Harris A.L. Clinical prognostic significance of tumor angiogenesis. Ann Oncol 5 (1994) 305-311
13. Barnhill R.L., and Levy M.A. Regressing thin cutaneous malignant melanomas (< or = 1.0 mm) are associated with angiogenesis. Am J Pathol 143 (1993) 99-104
14. Marcoval J., Moreno A., Graells J., Vidal A., Escriba J.M., Garcia-Ramirez M., et al. Angiogenesis and malignant melanoma: angiogenesis is related to the development of vertical (tumorigenic) growth phase. J Cutan Pathol 24 (1997) 212-218
15. Straume O., and Akslen L.A. Independent prognostic importance of vascular invasion in nodular melanomas. Cancer 78 (1996) 1211-1219
16. Graham C.H., Rivers J., Kerbel R.S., Stankiewicz K.S., and White W.L. Extent of vascularization as a prognostic indicator in thin (<0.76 mm) malignant melanomas. Am J Pathol 145 (1994) 510-514
17. Graff B.A., Bjornaes I., and Rofstad E.K. Microvascular permeability of human melanoma xenografts to macromolecules: relationships to tumor volumetric growth rate, tumor angiogenesis, and VEGF expression. Microvasc Res 61 (2001) 187-198
18. Byzova T.V., Goldman C.K., Pampori N., Thomas K.A., Bett A., Shattil S.J., et al. A mechanism for modulation of cellular responses to VEGF: activation of the integrins. Mol Cell 6 (2000) 851-860
19. Teraoka H., Sawada T., Nishihara T., Yashiro M., Ohira M., Ishikawa T., et al. Enhanced VEGF production and decreased immunogenicity induced by TGF-beta 1 promote liver metastasis of pancreatic cancer. Br J Cancer 85 (2001) 612-617
20. Lazar-Molnar E., Hegyesi H., Toth S., and Falus A. Autocrine and paracrine regulation by cytokines and growth factors in melanoma. Cytokine 12 (2000) 547-554
21. Dempke W., Rie C., Grothey A., and Schmoll H.J. Cyclooxygenase-2: a novel target for cancer chemotherapy?. J Cancer Res Clin Oncol 127 (2001) 411-417
22. Eisengart C.A., Mestre J.R., Naama H.A., Mackrell P.J., Rivadeneira D.E., Murphy E.M., et al. Prostaglandins regulate melanoma-induced cytokine production in macrophages. Cell Immunol 204 (2000) 143-149
23. Denkert C., Kobel M., Berger S., Siegert A., Leclere A., Trefzer U., et al. Expression of cyclooxygenase 2 in human malignant melanoma. Cancer Res 61 (2001) 303-308
24. Gallo O., Masini E., Bianchi B., Bruschini L., Paglierani M., and Franchi A. Prognostic significance of cyclooxygenase-2 pathway and angiogenesis in head and neck squamous cell carcinoma. Hum Pathol 33 (2002) 708-714
25. Khuri F.R., Wu H., Lee J.J., Kemp B.L., Lotan R., Lippman S.M., et al. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res 7 (2001) 861-867
26. Dohadwala M., Luo J., Zhu L., Lin Y., Dougherty C.J., and Sharma S. Non-small cell lung cancer cyclooxygenase-2-dependent invasion is mediated by CD44. J Biol Chem 276 (2001) 20809-20812
27. Sneath R.J., and Mangham D.C. The normal structure and function of CD44 and its role in neoplasia. Mol Pathol 51 (1998) 191-200
28. Johnson P., Maiti A., Brown K.L., and Li R. A role for the cell adhesion molecule CD44 and sulfation in leukocyte-endothelial cell adhesion during an inflammatory response?. Biochem Pharmacol 59 (2000) 455-465
29. Reis-Filho J.S., Milanezi F., and Schmitt F.C. Maspin is expressed in the nuclei of breast myoepithelial cells. J Pathol 197 (2002) 273-274
30. Reis-Filho J.S., Torio B., Albergaria A., and Schmitt F.C. Maspin expression in normal skin and usual cutaneous carcinomas. Virchows Arch 441 (2002) 551-558
31. Wada K., Maesawa C., Akasaka T., and Masuda T. Aberrant expression of the maspin gene associated with epigenetic modification in melanoma cells. J Invest Dermatol 122 (2004) 805-811
32. Srivastava A., Ralhan R., and Kaur J. Angiogenesis in cutaneous melanoma: pathogenesis and clinical implications. Microsc Res Tech 60 (2003) 208-224
33. Middleman B.R., Friedman M., Lawson D.H., DeRose P.B., and Cohen C. Melanoma growth stimulatory activity in primary malignant melanoma: prognostic significance. Mod Pathol 15 (2002) 532-537
34. Zhang M., Volpert O., Shi Y.H., and Bouck N. Maspin is an angiogenesis inhibitor. Nat Med 6 (2000) 196-199
35. Sheng S.J. The urokinase-type plasminogen activator system in prostate cancer metastasis. Cancer Metastasis Rev 20 (2001) 287-296
36. O'Meara M.M., Stea B., Rennels M., Lu D., Domann F., Hendrix M.J.C., et al. Loss of maspin expression in ductal carcinoma in situ of the breast. J Invest Med 51 (2003) S363
37. Boltze C., Schneider-Stock R., Meyer F., Peters B., Quednow C., Hoang-Vu C., et al. Maspin in thyroid cancer: its relationship with p53 and clinical outcome. Oncol Rep 10 (2003) 1783-1787
38. Fitzgerald M., Oshiro M., Holtan N., Krager K., Cullen J.J., Futscher B.W., et al. Human pancreatic carcinoma cells activate maspin expression through loss of epigenetic control. Neoplasia 5 (2003) 427-436
39. Lefter L.P., Sunamura M., Furukawa T., Takeda K., Kotobuki N., Oshimura M., et al. Inserting chromosome 18 into pancreatic cancer cells switches them to a dormant metastatic phenotype. Clin Cancer Res 9 (2003) 5044-5052
40. Zou Z.Q., Zhang W., Young D., Gleave M.G., Rennie P., Connell T., et al. Maspin expression profile in human prostate cancer (CaP) and in vitro induction of maspin expression by androgen ablation. Clin Cancer Res 8 (2002) 1172-1177
41. Fried L., and Arbiser J.L. The reactive oxygen-driven tumor: relevance to melanoma. Pigment Cell Melanoma Res 21 (2008) 117-122
42. Arbiser J.L. Molecular regulation of angiogenesis and tumorigenesis by signal transduction pathways: evidence of predictable and reproducible patterns of synergy in diverse neoplasms. Semin Cancer Biol 14 (2004) 81-91
43. Denk A.E., Bettstetter M., Wild P.J., Hoek K., Bataille F., Dietmaier W., et al. Loss of maspin expression contributes to a more invasive potential in malignant melanoma. Pigment Cell Res 20 (2007) 112-119
44. Odero-Marah V.A., Khalkhali-Ellis Z., Chunthapong J., Amir S., Seftor R.E.B., Seftor E.A., et al. Maspin regulates different signaling pathways for motility and adhesion in aggressive breast cancer cells. Cancer Biol Ther 2 (2003) 398-403
45. Arbiser J.L., Moses M.A., Fernandez C.A., Folkman J., Ghiso N., Cao Y., and Klauber N. Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways. Proc Natl Acad Sci U S A 94 (1997) 861-866
46. Yau L., and Zahradka P. PGE(2) stimulates vascular smooth muscle cell proliferation via the EP2 receptor. Mol Cell Endocrinol 203 (2003) 77-90
47. Tang K.Q., Nie D.T., Cai Y.L., and Honn K.V. The beta 4 integrin subunit rescues A431 cells from apoptosis through a PI3K/Akt kinase signaling pathway. Biochem Biophys Res Commun 264 (1999) 127-132
48. Govindarajan B., Bai X., Cohen C., Zhong H., Kilroy S., Louis G., et al. Malignant transformation of melanocytes to melanoma by constitutive activation of mitogen-activated protein kinase kinase (MAPKK) signaling. J Biol Chem 278 (2003) 9790-9795
49. Cohen C., Zavala-Pompa A., Sequeira J.H., Shoji M., Sexton D.G., Cotsonis G., et al. Mitogen-activated protein kinase activation is an early event in melanoma progression. Clin Cancer Res 8 (2002) 3728-3733